Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Aclaris Therapeutics

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Therapeutics
Public Companies

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes

July 1, 2025June 30, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its inclusion in the Russell 3000® and Russell 2000® Indexes, which became effective yesterday. This milestone marks a significant step …

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes Read More

Aclaris Therapeutics
Research

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052

June 23, 2025June 23, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More
Research

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment

June 2, 2025June 2, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …

Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More

Aclaris Therapeutics
Public Companies

Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025

May 29, 2025May 28, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in two healthcare conferences in June:

Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 Read More
Aclaris Therapeutics
Public Companies

Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025

May 12, 2025May 11, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that CEO Neal Walker and other senior leaders will join a virtual fireside chat as part of the HC Wainwright “HCW@Home” …

Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 Read More

Aclaris Therapeutics
Finance

Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates

May 11, 2025May 10, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) released its financial results for the first quarter of 2025, alongside updates on its expanding immuno-inflammatory (I&I) pipeline and leadership changes. The …

Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates Read More
Aclaris Therapeutics
Executives

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer

May 1, 2025April 30, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has named Jesse Hall, M.D., as its new Chief Medical Officer. Dr. Hall brings decades of expertise in medical and clinical development, …

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer Read More

Aclaris Therapeutics
Products and Services

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial

April 23, 2025April 22, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More
Aclaris Therapeutics
Public Companies

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences

March 5, 2025March 4, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its participation in two scheduled healthcare conferences in March 2025, where the company’s leadership team will provide insights into its …

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences Read More
Aclaris Therapeutics
Finance

Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025

February 28, 2025February 27, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its fourth quarter and full-year 2024 financial results, along with key pipeline advancements and corporate updates signaling a pivotal year ahead.

Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 Read More

Posts pagination

1 2 3 Next

Trending News

  • Pennsylvania Advances Elder Justice With New Multidisciplinary Team Initiative

  • Wilmington Police Investigating Saturday Night Shooting on West 6th Street

  • Wilmington Police Investigating Early Morning Shooting on Pleasant Street

  • Tower of Power to Bring Legendary Funk and Soul to Rivers Casino Philadelphia on August 1

  • Ginuwine to Bring Iconic R&B Hits to Rivers Casino Philadelphia on August 2

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Pennsylvania Department of Aging

Pennsylvania Advances Elder Justice With New Multidisciplinary Team Initiative

July 7, 2025July 7, 2025

Police news

Wilmington Police Investigating Saturday Night Shooting on West 6th Street

July 7, 2025July 7, 2025

Crime scene do not cross signage

Wilmington Police Investigating Early Morning Shooting on Pleasant Street

July 7, 2025July 7, 2025

Copyright © 2025 MyChesCo.